Anatolii Zagorodnii

Business Development (Freelance)

Anatolii is trained as an immuno-oncologist (MSc from University of Oxford; BSc from UCL), he combines strong scientific grounding with hands-on experience operating in the early-stage biotech startups within the UK’s rapidly growing life-sciences ecosystem.

Contributing Author

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Latest articles from Anatolii

UK Rolls Out National Strategy to Build Europe’s Life Sciences Powerhouse by 2030

The UK government has released a new Industrial Strategy white paper outlining plans to strengthen the country’s life sciences sector. Building on the previous green paper and industry consultations, the document proposes targeted investment, regulatory changes, and measures to support …

The Stage Is Set: London Biotechnology Show 2025

The inaugural London Biotechnology Show (LBS 2024) took place on 8–9 May 2024 at Olympia West, London, and culminated in an insightful discussion of emerging disruptive technologies such as AI in drug discovery, scalable cell and gene therapies and many …

A Call to Improve the UK Life Sciences Sector, Home to Over 6,800 Companies

In October 2024, the UK Government released an Industrial Strategy green paper outlining a 10-year plan for the sustainable economic growth of the country and initiating the dialogue with the public and industry representatives ahead of the white paper …